Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities

Shan Chung,1,* Valerie Quarmby,1 Xiaoying Gao,1 Yong Ying,1 Linda Lin,1 Chae Reed,1 Chris Fong,2 Wendy Lau,3 Zhihua J. Qiu,1 Amy Shen,4 Martin Vanderlaan2 and An Song1

1Department of BioAnalytical Sciences; Genentech, Inc.; San Francisco, CA USA; 2Department of Analytical Operations; Genentech, Inc.; San Francisco, CA USA; 3Department of Protein Analytical Chemistry; Genentech, Inc.; San Francisco, CA USA; 4Department of Early Stage Cell Culture; Genentech, Inc.; San Francisco, CA USA

Keywords: monoclonal antibody, antibody-dependent cellular cytotoxicity, FcγRIIIA, glycosylation, fucosylation, glycoform variants, afucosylated antibody

Abbreviations: AbX, a humanized anti-CD20 IgG1 antibody; ADCC, antibody-dependent cell-mediated cytotoxicity; AICC, antibody-independent cellular cytotoxicity; APTS, 8-aminopyrene-1,3,6-trisulfonic acid; BSA, bovine serum albumin; CDC, complement-dependent cytotoxicity; CDR, complementarity determining region; CE-LIF, capillary electrophoresis-laser induced fluorescence; CV, coefficient of variation; EC50, the concentration of test antibody at which 50% of its maximal binding activity is observed; EDTA, ethylene-diamine-tetra-acetic acid; ELISA, enzyme linked immunosorbet assay; Fab, fragment of antigen-binding; FBS, fetal bovine serum; Fc, fragment, crystalizable; GlcNAc, N-acetylglucosamine; G, glycoform, no terminal galactose on either arm of the oligosaccharide chain; G, glycoform, terminal galactose on one arm of the oligosaccharide chain; G0-F, afucosylated G0 glycoform; GST, glutathione S-transferase; HPMC, hydroxypropylmethyl-cellulose; HRP, horseradish peroxidase; IgG, immunoglobulin G; MSD, mess scale discovery; PBMC, peripheral blood mononuclear cells; PBS, phosphate buffered saline; PNGase F, peptide, N-Glycosidase F; RFU, relative fluorescence unit; RLU, relative luminescence unit; RT, room temperature; TMB, 3,3',5,5'-tetramethylbenzidine

The presence or absence of core fucose in the Fc region N-linked glycans of antibodies affects their binding affinity toward FcγRIIIa as well as their antibody-dependent cell-mediated cytotoxicity (ADCC) activity. However, the quantitative nature of this structure-function relationship remains unclear. In this study, the in vitro biological activity of an afucosylated anti-CD20 antibody was fully characterized. Further, the effect of fucose reduction on Fc effector functions was quantitatively evaluated using the afucosylated antibody, its “regular” fucosylated counterpart and a series of mixtures containing varying proportions of “regular” and afucosylated materials. Compared with the “regular” fucosylated antibody, the afucosylated antibody demonstrated similar binding interactions with the target antigen (CD20), C1q and FcγRIIa, moderate increases in binding to FcγRIIIa and IIb, and substantially increased binding to FcγRIIIa. The afucosylated antibodies also showed comparable complement-dependent cytotoxicity activity but markedly increased ADCC activity. Based on EC50 values derived from dose-response curves, our results indicate that the amount of afucosylated glycan in antibody samples correlate with both FcγRIIIa binding activity and ADCC activity in a linear fashion. Furthermore, the extent of ADCC enhancement due to fucose depletion was not affected by the FcγRIIIa genotype of the effector cells.

Introduction

The glycans attached to the asparagine at the 297 position (N297) of the Fc region of IgG play a critical role on the effector functions of antibodies.1-3 These N-linked glycans are situated within a cleft formed by the paired heavy chains in the CH2 domain of IgGs such that they may undergo extensive non-covalent interactions with the adjacent protein surface.4-6 There is evidence that interactions between the IgG Fc region and the effector ligands (Fcγ receptors and C1q) are critically dependent on IgG Fc protein–glycan interactions.7,8 Both the conformation and functionality of antibodies can be modulated by manipulation of these oligosaccharides.9,10 Antibodies depleted of N-linked glycans at Asn-297 behave similarly to normal antibodies with respect to antigen binding and Protein A binding capacity. However, they are defective in binding to Fcγ receptors, activating complement and inducing ADCC.4,11-13 Structural and thermodynamic data have shown that the precise structure of the IgG-Fc N-linked...
glycans helps to determine the binding affinity of the IgG to Fcγ receptors and thus the effector functions of the antibodies. Specifically, the N-glycans stabilize particular conformations of the CH2 domains and act as spacers, holding the CH domains apart to provide an open state of the horseshoe-shaped IgG-Fc fragment, allowing increased accessibility and tighter binding to Fcγ receptors.

The majority of human IgG-Fc N-linked glycans are based on a common core structure of biantennary heptapoly saccharide containing GlcNAc and mannose. Further modification of the core carbohydrate structure through the addition of fucose, as well as bisecting GlcNAc, galactose and sialic acid, substantially increases structural heterogeneity, with more than 30 variant forms possible. For both serum-derived endogenous human IgGs and IgG produced from engineered mammalian cell lines, the majority of Fc N-linked glycans carry different degrees of terminal galactosylation resulting in a G0, glycoform, a G1, glycoform and a G2, glycoform. Whereas these glycans are predominantly fucosylated, i.e., contain a fucose attached to the innermost GlcNAc residue in the core structure, small amounts of naturally occurring glycoforms that lack the core fucose have been observed in both human serum-derived and CHO cell produced IgG. It is well-documented that the absence of core fucose in IgG results in higher affinity binding to the FcγRIIIa receptor (both the F158 and V158 allotypes of this receptor) and increased ADCC activity. In 2002, Shields et al. first reported that recombinant human IgG1 produced from the CHO-Lec13 cell line showed enhanced FcγRIIIa binding and ADCC activity compared with IgGs produced by regular CHO cells. The CHO-Lec13 cell line is deficient in FUT8, the “regular” fucosylated AbX produced from a CHO cell line deficient in FUT8, the “regular” fucosylated AbX produced from CHO cells, and a series of mixtures with varying degrees of “regular” and afucosylated AbX. This sample set, hereafter referred to as AbX AF-blends, was quantitatively characterized in a series of in vitro assays including antigen (CD20) binding, Fcγ receptor binding, ADCC, C1q binding and CDC assays. Results from these studies were used to delineate the relationship between the relative activity of FcγRIIIa binding/ADCC and the level of afucosylated glycans in the antibody samples.

Results

Using capillary electrophoresis to determine fucosylation level. Fluorescent derivatives of glycans were released by PNGase F digestion and quantified by CE-LIF. Peaks were identified using a combination of known standards purchased commercially and enzymatic digests of the glycan structures. In this study, β-galactosidase was used to convert all glycans to the G0 form and the observed amount of G0-F reflected the aggregate of all non-fucosylated species (except the high mannose structures). The AbX AF-blends sample set consisted of 14 samples: the “regular” fucosylated (0% afucosylated AbX); the fucosylated (100% afucosylated AbX); and blended samples containing 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20% and 50% of the afucosylated AbX, with the “regular” fucosylated AbX added to make up the final content. Samples in the AbX AF-blends were identified by the content of the afucosylated AbX, including the starting material. Therefore “regular” fucosylated AbX is referred as 0% AF, whereas the afucosylated AbX is referred as 100% AF. An overlay of glycan analysis data from the various blends is shown in Figure 1. The increase in the level of G0-F is apparent, together with a corresponding decrease in G0F, as increasing amounts of afucosylated material are added to the blend.
AF-blends containing 0%, 5%, 10%, 20%, 50% and 100% afucosylated AbX. As expected, there were no discernible differences in CD20 binding among the AF-blends tested (Fig. 2).

C1q binding and CDC activities. The affect of fucose reduction on C1q binding was assessed by an ELISA using purified human C1q. Test antibodies included the “regular” fucosylated AbX (0% AF), the afucosylated AbX (100% AF) and 2 blended samples containing 10% and 50% afucosylated AbX (10% AF and 50% AF) respectively. As shown in Figure 3A, all four samples showed comparable C1q binding activity as demonstrated by overlapping dose-response curves. Further, the CDC activity of these samples was assessed in a cell-based assay using WIL2-S as target cells and complement derived from normal human serum. As shown in Figure 3B, comparable CDC activities were observed for all 4 AbX samples with varying degrees of afucosylated glycans. This finding is consistent with published literature, which reports that removal of core fucose in N-glycans of antibodies showed no affect on CDC activity of the antibodies.25

Fcγ receptor binding activity. The Fcγ receptor binding activity of AbX AF-blends was measured by ELISA-based methods using a panel of recombinant human Fcγ receptors (Ia, IIa-R131, IIb, IIIa-F158 and IIIa-V158). Antibody samples in...
monomeric form were tested for binding with the high-affinity receptor FcyRI (CD64) and in multimeric form (cross-linked with a F(ab')2 fragment of goat anti-human kappa chain) for binding with the low-affinity receptors, i.e., FcγRII (CD32) and FcγRIII (CD16). Twelve AbX AF-blends were tested for binding with FcγRII and FcγRIII, including those containing 0%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 15%, 20%, 50% and 100% of afucosylated AbX. Only six samples were tested for binding with FcγRI; the amount of afucosylated AbX in these samples were 0%, 5%, 10%, 20%, 50% and 100%.

Representative binding curves are shown in Figure 4. Overlapping dose-response curves were observed for the binding of AbX AF-blends to Fcy receptor Ia (Fig. 4A). The binding curves from samples containing increasing amounts of afucosylated glycans showed a small but apparent leftward shift for Fcy receptors Iia (Fig. 4B) as well as Iib (Fig. 4C) and a much more profound leftward shift for both allotypes of FcγRIIa (Fig. 4D and E). Overall, the extent of leftward shifts in binding curves among test samples appeared to be proportional to the respective content of afucosylated AbX. The leftward shift results in reduced EC50 value and is indicative of increased binding affinity. Overall, it appeared that removal of core fucose had a minimal affect on the binding of AbX with FcγRIla, moderate impact on the binding with Fcγ receptors Iia and Iib, and marked affect on the binding with IIIa. The assays were performed in multiple runs and the relative binding activity was calculated by inversely normalizing the EC50 values of test samples with those of the “regular” fucosylated AbX (0% afucosylated AbX). This exercise provided better quantification of the effect of afucosylation in different samples and allowed direct comparison of receptors with varying binding affinities. Of note, given that minimal differences were observed at upper asymptote of binding curves, it was justified to use EC50 values to calculate relative binding activity. The mean relative binding activity values are summarized in Table 2. Compared with the “regular” fucosylated AbX that had a relative binding activity value of 1, the afucosylated AbX showed a respective relative binding activity of 35 and 9 for F158 and V158; 3.6 and 2.4 for FcyRIIa and Iib, and 1.1 for FcγRIa.

The relative binding activity was plotted against the level of afucosylation and the data were fitted with a linear model to further examine the nature of the relationship between FcγRIIIa binding activity and afucosylation. Proportional increases in relative FcγRIIIa binding were observed for AF-blends with increasing amount of afucosylated AbX (Fig. 5A); the R-squared values for the linear fit with F158 and V158 allotypes are 0.994 and 0.985, respectively. Given that levels of afucosylated glycans in CHO cell-derived IgG are usually less than 10%, further analysis was performed using data generated from samples containing afucosylated glycan levels ranging from 0–10%. As shown in Figure 5B, a positive linear correlation between relative binding activity and the amount of afucosylated AbX in AF-blends (0%, 1%, 2%, 3%, 4%, 5%, 7.5% and 10%) was clearly demonstrated; the R-squared values for the linear fit with the F158 and V158 allotypes are 0.996 and 0.985, respectively. It is worth noting that this linear relationship was also observed with relative binding activity expressed as a function of the total content of afucosylated glycans represented by the theoretical G0-F and observed G0-F values (Table 1).

### Table 1. Levels of afucosylated glycans in AbX AF-blends

| Afucosylated Material | Theoretical G0-F (T) | Observed G0-F (O) | Difference (O-T)/T |
|-----------------------|----------------------|------------------|-------------------|
| 100%                  | 100%                 | 98%              | -2.2%             |
| 50%                   | 51%                  | 46%              | -8.6%             |
| 20%                   | 21%                  | 18%              | -15%              |
| 17.5%                 | 19%                  | 16%              | -16%              |
| 15%                   | 16%                  | 14%              | -16%              |
| 12.5%                 | 14%                  | 11%              | -16%              |
| 10%                   | 11%                  | 9.5%             | -15%              |
| 7.5%                  | 8.7%                 | 7.4%             | -15%              |
| 5%                    | 6.2%                 | 5.4%             | -13%              |
| 4%                    | 5.2%                 | 4.8%             | -8.2%             |
| 3%                    | 4.3%                 | 4.1%             | -4.0%             |
| 2%                    | 3.3%                 | 3.2%             | -3.8%             |
| 1%                    | 2.3%                 | 2.3%             | 0.1%              |
| 0%                    | 0%                   | 1.3%             | 1.3%              |

Theoretical G0-F was calculated assuming that the “regular” fucosylated material contains 1.3% afucosylated glycans and the afucosylated material contains 100% of afucosylated glycans; for example, the theoretical G0-F value of AbX AF-blend containing 10% afucosylated material is calculated as 0.1 x 100% + 0.9 x 1.3% = 11%. Observed G0-F values are obtained from the CE-based glycan analysis.

**ADCC assay.** The ADCC activity of selected AbX AF-blends was assessed using a human B lymphoma cell line, WIL2-S, as target cells and PBMC from healthy donors with predetermined FcγRIIIa genotype as effector cells. Due to constraints on the volume of fresh blood readily available, we tested 8 samples in this study: the “regular” fucosylated (0% AF-blend), the afucosylated (100% AF-blend), plus blended samples containing 2%, 5%, 7.5%, 10%, 20%, 50% and 100% of the afucosylated AbX. The study involved 16 donors: 5 were heterozygous for FcγRIIa-V158 (VV), 6 were heterozygous for FcγRIIIa-V158 (VV), and 6 were homozygous for FcγRIIIa (VF). Dose-response curves from representative experiments using effector cells carrying each of the 3 different FcγRIIIa genotypes as effector cells. Due to constraints on the volume of fresh blood readily available, we tested 8 samples in this study: the “regular” fucosylated (0% AF-blend), the afucosylated (100% AF-blend), plus blended samples containing 2%, 5%, 7.5%, 10%, 20%, 50% and 100% of the afucosylated AbX.

The relative ADCC activity of selected AbX AF-blends was tested in a ADCC assay. The ADCC activity of selected AbX AF-blends was assessed using a human B lymphoma cell line, WIL2-S, as target cells and PBMC from healthy donors with pre-determined FcγRIIIa genotype as effector cells. Due to constraints on the volume of fresh blood readily available, we tested 8 samples in this study: the “regular” fucosylated (0% AF-blend), the afucosylated (100% AF-blend), plus blended samples containing 2%, 5%, 7.5%, 10%, 20%, 50% and 100% of the afucosylated AbX. The study involved 16 donors: 5 were heterozygous for FcγRIIIa-F158 (FF), 5 were homozygous for FcγRIIIa-V158 (VV), and 6 were heterozygous (VF). Dose-response curves from representative experiments using effector cells carrying each of the 3 different FcγRIIIa genotypes (VV, VF and FF) are presented in Figure 6A–C. Consistent with published results,3,5,9 samples with higher levels of afucosylated material showed enhanced ADCC activity with effector cells from donors of all three FcγRIIIa genotypes as evidenced by leftward shifts, indicating reduced EC50 and higher upper asymptote, indicating increased maximal ADCC level. Of note, the differences in leftward shifts among samples appeared to be more profound than differences at the upper asymptote. Nevertheless, both changes appeared to correlate with the amount of afucosylated glycans in the sample. Figure 7A shows mean EC50 values calculated from dose-response curves fitted with a 4 Parameter Logistic nonlinear regression model. As evidenced by the large error bars, the variability for most of the mean values were high even though the data were calculated from donors carrying the same FcγRIIIa genotype. This wide range of variability is typical of ADCC assays using
the FcγRIIIa genotype of the effector cells. The relationship between the amount of afucosylated glycan and ADCC activity was further analyzed in a scatter graph (data not shown). A positive trend was observed where increasing amounts of afucosylated material generally led to higher levels of ADCC activity. Fitting the data to a linear model yielded R-squared values ranging from 0.94 to 0.97 depending on the FcγRIIIa genotype of the effector cells (data not shown). However, due to the wide range of afucosylated materials tested and the relatively small number of samples, specifically, those carrying low level (<10%) of afucosylated AbX, the resulting R-squared values from the linear fit might be skewed by samples carrying high levels of afucosylated material. Further, given the high variability of the PBMC-based ADCC assay, it is technically challenging to accurately detect small differences in ADCC activity associated with samples that contain a low level of afucosylated material. Engineered NK cell lines have been shown to behave similarly to purified NK cells and to offer improved performance in ADCC assays.36 To confirm the linear relationship between levels of afucosylated glycan and relative ADCC activity, additional ADCC studies were performed using an engineered NK cell line that expresses a high level of stably transfected human FcγRIIIa-F158 as effector cells. In this study, AbX AF-blends containing 0%, 1%, 2%, 3%, 4%, 5%, 7.5% and 10% of afucosylated material were tested in the NK cell line based ADCC assays. As shown in Figure 8, a linear relationship

PBMC as effector cells and is largely due to donor-to-donor variability. Additionally, we observed a notable rank order of EC_{50} values from donors with different FcγRIIIa genotypes (Fig. 7A). The lowest mean EC_{50} values came from effector cells carrying the VV genotype; the highest EC_{50} value came from FF effector cells; an intermediate EC_{50} value was obtained from effector cells from VF donors. This indicates that effector cells carrying VV genotype exert the highest level of ADCC activity, followed by those carrying VF, and the effector cells carrying the FF genotype have the lowest ADCC activity.

Relative ADCC activity was calculated by inversely normalizing the EC_{50} value of each sample to the EC_{50} value from the “regular” AbX (0% AF-blend) to better quantify the effect of fucose reduction on ADCC activity. The resulting mean relative ADCC activity values are summarized in Figure 7B. As evidenced by the reduced size of error bars compared with those in Figure 7A, normalization within a data set generated from a single donor significantly reduces the variability of the mean value; this confirms that the high variability seen in the raw data are primarily caused by inter-donor variability. Whereas EC_{50} values appear to differ according to the FcγRIIIa genotype of the effector cells (Fig. 7A), the relative ADCC activity in relation to the extent of afucosylated glycans remains similar despite the difference in FcγRIIIa genotypes (Fig. 7B). This result clearly demonstrates that the effect of fucose reduction on ADCC activity is independent of the FcγRIIIa genotype of the effector cells. The relationship between the amount of afucosylated glycan and ADCC activity was further analyzed in a scatter graph (data not shown). A positive trend was observed where increasing amounts of afucosylated material generally led to higher levels of ADCC activity. Fitting the data to a linear model yielded R-squared values ranging from 0.94 to 0.97 depending on the FcγRIIIa genotype of the effector cells (data not shown). However, due to the wide range of afucosylated materials tested and the relatively small number of samples, specifically, those carrying low level (<10%) of afucosylated AbX, the resulting R-squared values from the linear fit might be skewed by samples carrying high levels of afucosylated material. Further, given the high variability of the PBMC-based ADCC assay, it is technically challenging to accurately detect small differences in ADCC activity associated with samples that contain a low level of afucosylated material. Engineered NK cell lines have been shown to behave similarly to purified NK cells and to offer improved performance in ADCC assays.36 To confirm the linear relationship between levels of afucosylated glycan and relative ADCC activity, additional ADCC studies were performed using an engineered NK cell line that expresses a high level of stably transfected human FcγRIIIa-F158 as effector cells. In this study, AbX AF-blends containing 0%, 1%, 2%, 3%, 4%, 5%, 7.5% and 10% of afucosylated material were tested in the NK cell line based ADCC assays. As shown in Figure 8, a linear relationship

---

**Figure 2.** Antigen binding activity of select AbX AF-blends measured in a cell-based binding assay. Human B lymphoma cell line WIL2-S were coated on plates and incubated with various concentrations of AbX AF-blends. Antibodies bound to CD20 on WIL2-S were detected with goat anti-human IgG polyclonal antibodies. Results for AbX AF-blends containing 0% (○), 5% (□), 10% (△), 20% (○), 50% (●) and 100% (■) of the afucosylated material are shown. RLU, relative luminescence unit.
between relative ADCC activity and the amount of afucosylated glycan in the AF-blends was clearly demonstrated; the R-squared value for the linear fit was 0.967.

**Effect of afucosylated glycans in AbX production batches on FcγRIIIa binding and ADCC activities.** Ten samples of AbX from different production runs were evaluated to verify the effects of afucosylated glycans on effector functions of AbX samples produced from wild type CHO cells. The relative FcγRIIIa-F158 binding and relative ADCC activity were plotted against the level of afucosylated glycans (% G0-F) measured by glycan analysis. As shown in **Figure 9A and B**, linear relationships between the amount of afucosylated glycan and either the relative FcγRIIIa-F158 binding activity or the level of relative ADCC activity based on EC₅₀ values were clearly demonstrated. The R-squared value for the FcγRIIIa binding data are 0.9688; the R-squared value for the relative ADCC data are 0.9674.

**Discussion**

Removal of core fucose from IgG-Fc N-glycans has been shown to enhance FcγRIIIa binding and ADCC activity of antibodies. Structural models indicate that the core fucose in Fc N-glycan may present steric hindrance for the FcγRIII glycan at N162, thereby preventing optimal interactions between the antibody and the receptor. For therapeutic antibodies produced from mammalian cell lines, some variation in the level of afucosylated glycans is routinely observed in different production batches. Although these differences are usually small, given the effect of afucosylated glycan on FcγRIIIa binding and ADCC, it is important to monitor the content of afucosylated glycan in the antibody product during production processes and assess the affect on biological activities with appropriate assays. In this study, we sought to quantitatively characterize effects of fucose reduction on in vitro biological activities of a humanized antibody. The results of our study confirm that the content of afucosylated glycans in antibodies does not affect target binding, C1q binding and CDC activity. More importantly, our data show a strong linear correlation between levels of afucosylated glycans and both the FcγRIIIa binding and ADCC activity of the antibody.

Fcγ receptors play a vital role in the in vivo mechanisms by which antibodies mediate their activity. Activating Fcγ receptors such as FcγRIIa and IIId are involved in activation of cytotoxic activity of effector cells such as NK cells, monocytes, macrophages and neutrophils. On the other hand, the inhibitory FcγRIIB has been shown to modulate B cell activity, humoral tolerance and plasma-cell survival. Since many cell types co-express activating and inhibitory Fcγ receptors, the effector functions of therapeutic antibodies are counterbalanced by differential interactions with both the activating FcγRIIa/IIId and the inhibitory FcγRIIB. The outcome of these interactions may influence both the efficacy and safety of the therapeutic antibodies. Using ELISA-based binding assays, we showed that increasing the afucosylated glycan content of AbX led to markedly increased binding activity toward FcγRIIIa, moderate increases in IIa and IIb binding, but no affect on binding with Ia. While it is difficult to ascertain the biological significance of the moderate increase in binding with FcγRIIIa and IIb by afucosylated antibodies, the increase in binding activity toward FcγRIIIa appeared to result in proportional increase in ADCC activity. Additionally, the changes in afucosylated glycan content and relative ADCC potency derived from normalized EC₅₀ values appeared to correlate in a linear fashion. Given that this linear relationship was also observed among samples carrying low (<10%) levels of afucosylated glycans, it is clear that small differences in levels of afucosylated glycans routinely observed in production batches of CHO cell produced antibody products can result in considerable changes in biological activity. Due to the lack of clinical data and the complexity of molecular mechanisms underlying immune effector functions, the significance of these differences relative to the in vivo functions of AbX remains unclear. However, it does not minimize the importance of monitoring levels of afucosylated glycans in antibody products. Currently, there are several engineered antibodies with improved effector functions under clinical development; the availability of
dose-response curves, we were able to quantify the increase in ADCC activity in relation to varying levels of afucosylated glycans in the AbX AF-blends. Our data clearly indicate that increasing levels of afucosylated glycans lead to increased ADCC activity and that the extent of increase correlates linearly with the amount of afucosylated glycans. Furthermore, the extent of data from these clinical studies should further our understanding on the correlation between in vitro effector functions and in vivo efficacy of a therapeutic antibody.

The in vitro ADCC activities of the AbX AF-blends were assessed using PBMC from donors with pre-determined FcγRIIIa genotypes. Based on EC_{50} values derived from complete dose-response curves, we were able to quantify the increase in ADCC activity in relation to varying levels of afucosylated glycans in the AbX AF-blends. Our data clearly indicate that increasing levels of afucosylated glycans lead to increased ADCC activity and that the extent of increase correlates linearly with the amount of afucosylated glycans. Furthermore, the extent of

**Figure 4.** Binding responses of AbX AF-blends to human Fcγ receptors. Dose-response binding curves of AbX AF-blends to various human Fcγ receptors were generated from ELISA-based binding assays using soluble recombinant Fcγ receptors. The test antibodies were assayed in monomeric form for (A) Fcγ Receptor Ia, and in multimeric forms for (B) Ila-R131, (C) IIb, (D) IIIa-F158, (E) IIIa-V158. All data points were collected in duplicate and the mean absorbance values from duplicate wells at OD 450 nm were plotted against the antibody concentration. Binding curves for 0% (blue ○), 2% (green □), 5% (orange △), 7.5% (magenta ◇), 10% (gray ●), 20% (brown ■), 50% (purple ▲), 100% (red◆) of the afucosylated material are shown. The results shown were obtained from one representative data set out of at least three in vitro binding experiments.
increase in ADCC activity appeared to be minimally affected by FcγRIIIa genotypes because AbX AF-blends showed comparable relative ADCC activity regardless of the FcγRIIIa genotype of the effector cells. Overall, our data indicate an 8–10-fold increase in ADCC activity with afucosylated AbX over the regular fucosylated AbX. Some previous studies reported substantially higher (>100 fold) increases in ADCC activity due to fucose depletion.23,39 However, the quantification in those studies was largely based on estimated values extrapolated from incomplete dose-response curves. In contrast, our data was based on multiple samples with varying degrees of reduction in afucosylated glycans and relative ADCC activity quantified with EC50 values derived from complete dose-response curves. In addition, the approximately 10-fold increase in ADCC activity found in afucosylated AbX was also observed in assays using either fresh NK cells or engineered NK cell lines as target cells (unpublished data). It is worth noting that whereas proportional shifts were observed toward higher maximal levels of ADCC at saturating concentrations, reflecting improvements in the relative efficacy of the variants, the differences were typically within a two-fold range. This limited range of the upper asymptote, which represents maximum ADCC activity, justifies the use of EC50 values as an expression of relative ADCC activity. However, this approach to quantification might under-estimate the effects by failing to account for changes in the upper asymptote of the dose-response curves. Nevertheless, given that movements in the upper asymptote were also proportional to levels of afucosylated glycans in the samples, the omission of this parameter should not compromise the validity of the observed linear relationship between the afucosylated glycan level and the ADCC activity.

Table 2. Summary of mean relative Fcγ receptor binding activity of AbX AF-blends

| Percent | Afucosylated Material | FcγRlla-F158 Mean (n = 6) | SD | FcγRlla-V158 Mean (n = 6) | SD | FcγRlla-R131 Mean (n = 4) | SD | FcγRlib Mean (n = 4) | SD | FcγRla Mean (n = 3) | SD |
|--------|----------------------|---------------------------|----|--------------------------|----|--------------------------|----|---------------------|----|---------------------|----|
| 0%     | 0% afucosylated material | 1.00 | NA | 1.00 | NA | 1.00 | NA | 1.00 | NA | 1.00 | NA |
| 1%     | 1.34 | 0.11 | 1.10 | 0.26 | 1.16 | 0.09 | 1.13 | 0.01 | ND | NA |
| 2%     | 1.49 | 0.16 | 1.16 | 0.17 | 1.37 | 0.18 | 1.31 | 0.03 | ND | NA |
| 3%     | 1.78 | 0.14 | 1.24 | 0.28 | 1.34 | 0.10 | 1.26 | 0.10 | ND | NA |
| 4%     | 1.96 | 0.24 | 1.32 | 0.21 | 1.35 | 0.04 | 1.27 | 0.00 | ND | NA |
| 5%     | 2.31 | 0.22 | 1.55 | 0.44 | 1.30 | 0.08 | 1.20 | 0.05 | 0.88 | 0.06 |
| 7.5%   | 2.81 | 0.31 | 1.81 | 0.50 | 1.62 | 0.02 | 1.60 | 0.09 | ND | NA |
| 10%    | 3.34 | 0.12 | 2.05 | 0.50 | 1.64 | 0.16 | 1.38 | 0.02 | 1.00 | 0.04 |
| 15%    | 4.35 | 0.36 | 2.53 | 0.47 | 1.72 | 0.01 | 1.63 | 0.03 | ND | NA |
| 20%    | 6.00 | 0.46 | 2.98 | 0.76 | 1.66 | 0.11 | 1.50 | 0.22 | 0.94 | 0.03 |
| 50%    | 15.7 | 1.23 | 6.12 | 0.75 | 2.29 | 0.08 | 1.70 | 0.15 | 0.98 | 0.04 |
| 100%   | 34.9 | 6.25 | 9.05 | 0.80 | 3.62 | 0.42 | 2.40 | 0.13 | 1.13 | 0.11 |

Relative Fcγ receptor binding activity = [EC50 0% afucosylated material/ EC50 sample]. SD = standard deviation; NA = not applicable; ND = not done.

Figure 5. Correlation between relative FcγRlla binding activity and amount of afucosylated materials in AbX AF-blends. Relative binding activity was calculated by inverse normalization of EC50 values of samples with EC50 of the sample containing 0% of the afucosylated material (100% “regular” fucosylated material). Mean relative binding activity values (Table 2) were plotted against levels of afucosylated material in the samples and the data points were fitted to a linear model using Excel.
product release testing, the most relevant biological activity (potency) of the product is typically measured by quantitative comparison of dose-dependent response of reference and sample preparations in a precise and accurate manner to ensure manufacture consistency. A more precise and accurate measurement of ADCC activity of antibody product that takes into account the differences in the upper asymptote may be achieved by employing a parallel-logistics assay where parallelism assessment is part of the system suitability criteria and relative ADCC potency is measured with a constrained 4- or 5-parameter parallel curve model.

The ability of antibodies to induce ADCC depends on the binding affinities to both the antigen on target cells and to the Fcγ receptors on effector cells. One of the factors that influences binding affinity between IgG and FcγRIIIa is the genetic polymorphism in FcγRIIIa that results in the expression of valine (V) or phenylalanine (F) at amino acid 158. Structural and functional studies have shown that FcγRIIIa residue 158 is directly involved in hydrophobic contact with IgG-Fc and that the FcγRIIIa-V158 allotype binds to IgG1 with higher affinity than the FcγRIIIa-F158 allotype. Additionally, immune effector cells bearing the FcγRIIIa-V158 allele have been shown to mediate more potent ADCC activity than those bearing the F allele in in vitro ADCC assays. Further, clinical studies have shown that non-Hodgkin lymphoma patients carrying the FcγRIIIa-V158 allotype responded better to rituximab treatment than those carrying the FcγRIIIa-F158 allotype. Similar findings were also reported for breast cancer patients treated with trastuzumab. Consistent with these published reports, we observed a clear and notable rank order of EC50 values from donors with different FcγRIIIa genotypes. The lowest EC50 values (highest ADCC activity) came from effector cells carrying VV genotypes; the highest EC50 value came from FF effector cells; an intermediate EC50 value was obtained with effector cells from theVF donors. This result confirms that immune effector cells bearing the FcγRIIIa-V158 allele are generally more potent in inducing ADCC activity than those bearing the F158 allele. In spite of such differences in ADCC potency, effector cells carrying different FcγRIIIa genotypes showed similar degrees of increase in relative ADCC activity by AbX AF-blends in our assays, indicating that the effect of N-glycan fucose reduction on ADCC activity of the antibody is independent of the FcγRIIIa genotype of the effector cells.

Afucosylated glycan content, in contrast, had a more profound affect on binding activity toward FcγRIIIa-F158 in the ELISA based binding assays. Specifically, compared with the “regular” fucosylated AbX, there were 9- and 35-fold increases in the afucosylated AbX for binding with FcγRIIIa-V158 and F158, respectively. This discrepancy could be due to differences in assay systems and the sample preparation involved in the ELISA method. Due to the low binding affinity, binding between monomeric IgG and FcγRII and III could not be detected in ELISA-based assays, which required multiple washing cycles between each incubation step. To overcome this obstacle, the samples of antibodies were routinely tested in multimeric forms via cross-linking with anti-kappa F(ab’)2. It is conceivable

![Figure 6](image-url)
effector function assays is typically based on the effector function potential of the product and depends on its IgG subclass, glycoform and mechanism of action, as well as the biological property of the target molecule. For antibody products where Fc effector function is a part of the mechanism of action, effector function testing should be tightly coordinated with other analytical assessments of product quality attributes. The characterization of IgG1 Fc glycosylation is of particular importance because of the established correlation between fucose reduction and effector functions.

In both serum-derived IgG and IgG produced from CHO cells with conventional processes, there are typically less than 10% afucosylated glycans. An antibody could carry an afucosylated N-glycan in each of the two heavy chains. However, given the small amount of the afucosylated glycans present and the fact that glycan biosynthesis is intrinsically random as well as heterogeneous, it is more likely that most naturally occurring afucosylated glycans exist in antibodies that are half-afucosylated, that is, where one heavy chain carries an afucosylated glycan and the other heavy chain in the same molecule carries a fucosylated glycan. Crystal structures show that the Fcγ receptor binding site on IgG-Fc is localized to the hinge proximal region of the CH2 domain and includes the lower hinge region. More importantly, the binding site is asymmetrical with both heavy chains making contact with a single FcγRIII molecule, which dictates that one receptor can only bind to one IgG-Fc at a time. This 1:1 stoichiometry of the IgG-Fc/FcγRIII complex is critical for normal immune functions because it prevents constant stimulation of the immune system by monomeric immunoglobulins that are present at high concentrations in the serum. The structural model of IgG-Fc/FcγRIII complex also predicts that only one of the two Fc-fucose residues needs to be absent for increased binding affinity toward FcγRIII. It implies that a homogenously afucosylated antibody should behave similarly to a half-afucosylated antibody in terms of FcγRIII binding and ADCC activities. Most of the data in this study were generated from antibody samples carrying mixtures of homogenously fucosylated or homogenously afucosylated glycans and not from half-afucosylated antibodies. To ensure that our findings are generally applicable to “regular” antibody samples, a panel of 10 AbX samples produced from wild-type CHO cells were evaluated for the FcγRIIIa binding and ADCC activities. Linear relationships between the amount of afucosylated glycans and either the FcγRIIIa binding activity or the ADCC activity were clearly demonstrated, suggesting that the quantitative data generated by blended samples can be extended to batch samples that presumably contain mostly half-afucosylated antibodies. The observation of over three-fold increase in ADCC activity with product batches containing varying amount of afucosylated glycans demonstrates that glycoform can profoundly influence effector functions of the product and underscores the importance to better control the production process to provide adequate manufacturing consistency. However, controlling glycoform fidelity remains a huge challenge to pharmaceutical industry to date. Manipulation of that cross-linked samples with high afucosylated glycan content might exert avidity approaching the limit of the dynamic range of the assay, resulting in under-quantification of the binding activity with the V158 allotype. Further, additional binding studies using a surface plasmon resonance-based immunoassay showed comparable changes of 20-fold in binding affinity between “regular” and afucosylated AbX for both FcγRIIIA allotypes (unpublished data). Together, the present observation of the differential affect of afucosylated glycans on the binding with FcγRIIIA allotypes is likely due to inherent limitation of the ELISA-based assay system.

During clinical development and manufacturing, different assay strategies appropriate to different types of antibody products should be devised to assess effector functions. Selection of
Materials and Methods

Preparation of AbX AF-blends. AbX is a humanized anti-CD20 antibody based on IgG1 heavy chains and kappa light chains. For this study, greater than 98% fucosylated AbX was produced from the CHO DP12 cell line. Completely afucosylated AbX was produced from a CHO cell line deficient in FUT8. Both materials showed comparable physicochemical properties including purity, solubility and low level of high mannose glycoform or aggregation (data not shown). Blends of afucosylated variants were generated by mixing the “regular” fucosylated antibodies with the afucosylated materials. The resulting AbX AF-blends consisted of 14 samples: the “regular” fucosylated, the afucosylated, plus blended samples containing 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20% and 50% of the afucosylated AbX. “Regular” fucosylated AbX was added to make up the final content. Of note, samples in the AbX AF-blends were identified by the content of the afucosylated antibodies with the afucosylated materials. The resulting AbX AF-blends consisted of 14 samples: the “regular” fucosylated, the afucosylated, plus blended samples containing 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20% and 50% of the afucosylated AbX. “Regular” fucosylated AbX was added to make up the final content. Of note, samples in the AbX AF-blends were identified by the content of the afucosylated AbX, including the starting material. Thus, the “regular” fucosylated sample is referred as 0% AF, whereas the afucosylated AbX is referred as 100% AF.

Using CE-LIF to determine the fucose content of antibody glycans. The fucose content of Fc glycans was determined by CE using a LIF method as the detection mode. Briefly, the samples

Figure 8. Activity of AbX samples consisting of varying mixtures of fucosylated and afucosylated materials in ADCC assays using an engineered NK cell line as effector cells. The engineered NK cell line expresses stably transfected human FcγRIIIa-F158 and was used in conjunction with the human B lymphoma WIL2-S as target cells at an effector cell/target cell ratio of 5:1. The extent of cell lysis was measured by LDH activity assay. Samples tested included those containing 0%, 1%, 2%, 3%, 4%, 5%, 7.5% and 10% of afucosylated material. Data presented are mean values from three in vitro ADCC experiments; error bars indicate corresponding standard deviations. Relative ADCC activity was calculated by inverse normalization of EC₅₀ values of samples with EC₅₀ value of the sample containing 0% afucosylated material. The data was fitted to a linear model using Excel.
(300 μg) were transferred to pH 7.5 buffer containing 20 mM sodium phosphate, 50 mM EDTA and 0.02% NaN₃; then digested with 10 milliunits of PNGase F (New England Biolabs, Ipswich, MA) for 15 h at 37°C. The antibody was precipitated by heating the solution at 95°C for 5 min and the precipitate was removed by centrifugation. The supernatant solutions were further treated with 10 milliunits of β-galactosidase (Prozyme) for 2 h at 37°C. The solutions were then dried in a centrifugal vacuum evaporator and the released glycans were used to generate derivatives with APTS (Beckman Coulter) in a 15% acetic acid solution containing sodium cyanoborohydride. The derivative formation reaction was conducted for 2 h at 55°C. A Beckman PA-800 system was used for the CE analysis in a running buffer of 40 mM ε-amino caproic acid/acetic acid (pH 4.5) and 0.2% HPMC. This system was equipped with a N-CHO coated capillary (50 μm i.d. × 60.2 cm, Beckman Coulter) and a LIF detection module using an argon-ion laser (488 nM excitation, 520 nM emission). A water plug was injected into the capillary at 0.2 psi for 5 sec prior to sample loading. Samples were then injected into the capillary at 0.5 psi for 10 sec. The separation of the oligosaccharide derivatives was performed at 500 V/cm (30 kV) with the capillary temperature maintained at 20°C.

**CD20 binding assay.** Binding of AbX to CD20 antigen was measured using a cell-based electrochemiluminescent assay as described by Lu et al. Briefly, WIL2-S cells, a human B lymphoma cell line expressing a high level of CD20, were washed with phosphate buffered saline (PBS) and seeded at 25,000 cells/well in 25 μL PBS on 96-well MULTI-ARRAY High Bind plates (MSD). WIL2 cells were incubated for one hour at room temperature (RT) to allow cell attachment to the carbon surface. The plates were then blocked with 15% FBS in PBS for 30 min at RT with mild agitation and incubated with serial dilutions of antibodies (2.74–2,000 ng/mL) in assay buffer (PBS containing 10% FBS). After 1 h incubation at RT with mild agitation, the plates were washed and bound antibodies were detected by adding ruthenium-labeled F(ab)₂, goat anti-human IgG Fc in assay buffer in the presence of Tris-based Read Buffer T (MSD). Upon electrochemical stimulation, luminescent signals were quantified with a Sector Imager 6000 reader (MSD). Dose-response binding curves were generated by plotting the mean luminescent signals from duplicates of sample dilutions against the sample concentrations and fitting the data points to a four-parameter model using SoftMax Pro (Molecular Devices).

**Fcγ receptor binding by ELISA.** The binding activities of test antibodies toward various human Fcγ receptors were assessed by ELISA-based ligand binding assays. The human Fcγ receptors were expressed as fusion proteins containing the extracellular domain of the Fcγ receptor linked to a Gly/6x His/glutathione S-transferase (GST) polypeptide tag at the C-terminus. For the low-affinity receptors [FcγRIIa (CD32A), Fcγ RIib (CD32B) and Fcγ RIla (CD16)], antibodies were tested as multimers by cross-linking with F(ab)₂ fragments of goat anti-human kappa chain antibodies (MP Biomedicals) at an approximate molar ratio of 1:3. For the high-affinity receptor (FcγRIa), the antibodies were assayed as monomers without cross-linking. Sample and reagent dilutions were prepared in an assay buffer containing PBS, 0.5% BSA and 0.05% Tween-20. Plates were washed with PBS containing 0.05% Tween-20 using an ELx405™ plate washer (Biotek Instruments) after each incubation step. Plates were coated with an anti-GST antibody (Genentech) in a 0.05 M sodium carbonate buffer (pH 9.6) overnight at 4°C. After blocking with the capture antibody, the plates were incubated with Fcγ receptors for 1 h at RT. Serially diluted test antibodies were added either as monomers (for binding with FcγRIa) or as multimeric complexes (for binding with FcγRIIa, Iib and IIIa) and the plates were incubated for 2 h at RT. Antibodies bound to the Fcγ receptor were linked to HRP conjugated F(ab)₂ fragment of goat anti-human F(ab)₂ (Jackson ImmunoResearch Laboratories, West Grove, PA) and substrate TMB (Kirkegaard and Perry Laboratories, Gaithersburg, MD) was added. The plates were incubated for 5–20 min at RT, depending on the Fcγ receptors tested, to allow color development. The reaction was...
terminated with 1 M H₃PO₄ and absorbance determined at 450 nm. Dose-response binding curves were generated by plotting the mean absorbance values from duplicates of sample dilutions against the sample concentrations and fitting the data points to a four-parameter model using SoftMax Pro (Molecular Devices) to obtain the EC₅₀ values. For comparison, relative activity was calculated for each sample by inversely normalizing its EC₅₀ value with that of a reference molecule using the following formula:

Relative Activity = EC₅₀ Reference/EC₅₀ Sample

**ADCC assay.** ADCC assays were performed using PBMC from healthy donors as effector cells and WIL2-S, a human B lymphoma cell line, as target cells. Briefly, PBMC were isolated from fresh blood of healthy human donors by Ficoll-Paque (GE Healthcare, Milwaukee, WI) density gradient centrifugation. Target cells (4 × 10⁴) prepared in assay medium (RPMI 1640 with 1% BSA and 100 units/mL penicillin and streptomycin) were added to each well in round-bottom, 96-well tissue culture plates. Serial dilutions of antibodies (10,000 to 0.0038 ng/mL) were added to each well in round-bottom, 96-well tissue culture plates. Serial dilutions of antibodies (10,000 to 0.0038 ng/mL following 4-fold dilutions in series) were added to the plates containing the target cells (50 μL/well) and incubated for 30 min at 37°C with 5% CO₂ to allow opsonization. After incubation, PBMC (1.0 × 10⁶) were added to each well, in assay medium, for a 25:1 effector:target cell ratio and the plates were incubated further for 4 h. The plates were then centrifuged and the supernatants were assayed for lactate dehydrogenase activity using a Cytotoxicity Detection Kit (Roche Diagnostics Corporation). Cell lysis was quantified by measuring absorbance at 490 nm using a microplate reader SpectraMax®190 (Molecular Devices). Absorbance of wells containing only the target cells served as the control for background (Low Control), whereas wells containing target cells lysed with Triton-X100 provided the maximum available signal (High Control). AICC was measured in wells containing target and effector cells without the antibody.

The extent of specific ADCC was calculated as follows:

%ADCC = [A₄₉₀ nm (sample) - A₄₉₀ nm (AICC)]/[A₄₉₀ nm (High Control) - A₄₉₀ nm (Low Control)]

Dose-response curves were generated by plotting the mean ADCC values from duplicates of antibody sample dilutions against the antibody concentration. The EC₅₀ values were calculated by fitting the data points to a four-parameter equation using SoftMax Pro. For comparison, relative activity was calculated for each sample by inversely normalizing its EC₅₀ value with that of a reference molecule using the following formula:

Relative Activity = EC₅₀ Reference/EC₅₀ Sample

In select experiments, an engineered NK cell line expressing stably transfected human FcγRIIIa-F158 was used as effector cells, but the effector:target cell ratio was changed to 5:1 and the incubation time was reduced to 3 h. The rest of the procedures were the same as described above.

**C1q binding assay.** Human C1q binding to AbX-AF blends was measured by ELISA. Antibodies were serially diluted and coated on high binding microtiter plate wells at 2–8°C with overnight incubation. The plates were sequentially incubated with 2 mg/mL human C1q (Quidel Corporation) for 2 h at RT, goat anti-human C1q (Accurate Chemical, Westbury, NY) for 1 h at RT, and donkey anti-goat IgG-HRP (Millipore) for 1 h at RT after blocking with 3% BSA/PBS (1 h at RT). Plates were washed with PBS containing 0.05% Tween-20 using an ELx405 plate washer (Biotek Instruments) after each incubation step. Peroxidase activity was detected with TMB substrate (Kirkegaard and Perry Laboratories) and the plates incubated at RT for 15 min to allow color development. The reaction was terminated with 1 M H₃PO₄ and absorbance measured at 450 nm (the background measured at 650 nm was subtracted for each well) using a microplate reader SpectraMax®190 (Molecular Devices). Dose-response binding curves were generated by plotting the mean absorbance values from duplicates of sample dilutions against the sample concentrations and then fitting the data points to a four parameter logistic model using SoftMax Pro. In a separate experiment, an anti-human Fab-HRP conjugate (Jackson ImmunoResearch Laboratories) was used to determine equivalent coating of antibodies to the wells of the microtiter plate.

**CDC assay.** CDC activities of test antibodies were assessed by a cell-based assay using WIL2-S cells as target cells. AbX-AF blends were serially diluted in assay medium (RPMI 1640 medium supplemented with 1% FBS) and distributed into a 96-well opaque-walled microtiter plate (Costar Corning Inc.). The plate was incubated with 5% CO₂ for 2 h at 37°C after WIL2-S cells (5 × 10⁶ cells/well) and normal human serum complement (Quidel Corporation) were added. After the incubation, the CellTiter-Glo reagent (Promega Corp.), which assays for ATP in metabolically active cells, was added and the plate was incubated for 10 min at RT with constant shaking. The extent of cell lysis was quantified by measuring intensity of luminescence with a plate reader SpectraMax M5 (Molecular Devices). Dose-response binding curves were generated by plotting the mean luminescence signal from duplicates of sample dilutions against the sample concentrations and then fitting the data points to a four-parameter model using SoftMax Pro (Molecular Devices).

**Disclosure of Potential Conflicts of Interest**

All the authors are employees of Genentech, Inc., which supported the study financially.

**Acknowledgements**

The authors would like to thank Patty Siguenza for support on the project, Kyra Cowan and Bob Kelley for helpful comments on the manuscript, and colleagues at the research blood program, the sample transportation program, and the CritRS group for providing critical reagents.
References

1. Jeffers R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharm Sci 2007; 28:356-62; PMID:17552968; http://dx.doi.org/10.1016/j.tips.2007.04.007.

2. Raju TS. Terminal sugars of FeC glycans influence antibody effector functions of IgGs.Curr Opin Immunol 2008; 20:471-8; PMID:18686225; http://dx.doi.org/10.1016/j.coi.2008.06.007.

3. Jiang XR, Song A, Bergelson S, Arrol T, Parakh B, May K, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101-11; PMID:21283105; http://dx.doi.org/10.1038/nrd3565.

4. Sondermann P, Huber R, Osuchowin V, Jacob U. The 3.2-A crystal structure of the human IgG fragment-Fc gammaRIII complex. Nature 2000; 406:267-73; PMID:11917521; http://dx.doi.org/10.1038/sj.emm.13018508.

5. Rades R, Moriya S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III FcgammaRI in complex with FeC. J Biol Chem 2001; 276:16469-77; PMID:11975352; http://dx.doi.org/10.1074/jbc.M10305200.

6. Sondermann P, Kaiser J, Jacob U. Molecular basis for immune complex recognition: a comparison of Fc receptor structures. J Mol Biol 2001; 305:73949; PMID:11397093; http://dx.doi.org/10.1006/jmbi.2001.4670.

7. Jeffers R, Lund J. Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol Lett 2002; 82:57-65; PMID:12088035; http://dx.doi.org/10.1016/S0165-2478(02)00019-6.

8. Krapp S, Moriya S, Jeffers R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation profiles and modulation of the dynamic motion of the FeC oligosaccharides. Biochemistry 1997; 36:1370-80; PMID:9063885; http://dx.doi.org/10.1021/bi9621472.

9. Saba JA, Kunzel JP, Jan DK, Eme W, Standing KG, Butler M, et al. A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electro spray and matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 2002; 305:16-31; PMID:12018942; http://dx.doi.org/10.1016/S0003-2697(02)00531-0.

10. Parakh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316:452-7; PMID:3927174; http://dx.doi.org/10.1038/sj.emm.13018508.

11. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 1985; 54:631-64; PMID:3896128; http://dx.doi.org/10.1146/annurev.bi.54.070185.005215.

12. Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, et al. Lack of fucosylation in human IgG1 N-linked oligosaccharide improves binding to human FcgammaRII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202692000.

13. Niwa R, Hattori M, Shoji-Hasoka S, Sakurada M, Kobayashi Y, Uehara A, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004; 10:6248-55; PMID:15440014; http://dx.doi.org/10.1158/1078-0432.CCR-04-0850.

14. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushita K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11:2327-36; PMID:15788684; http://dx.doi.org/10.1158/1078-0432.CCR-04-2463.

15. Ferrara C, Br¨unker P, Surter T, Mose S, Puntenner U, Umata P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta 1-4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biochemical Biotechnol Bioeng 2006; 93:851-61; PMID:16435400; http://dx.doi.org/10.1002/bit.20777.

16. Lund J, Takahashi N, Pound JD, Goodall M, Nakagawa H, Jeffers R. Oligosaccharide-protein interactions in IgG can modulate receptor binding by gamma receptors. FASEB J 1995; 9:1159; PMID:8271750.

17. Radev S, Sun PD. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem 2001; 276:1647883; PMID:11297553; http://dx.doi.org/10.1074/jbc.M10351200.

18. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg JG, Dwek RA. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Immunol Lett 1999; 36:1370-80; PMID:9063885; http://dx.doi.org/10.1016/S0165-2478(02)00531-0.

19. Niwa R, Hattori M, Shoji-Hasoka S, Sakurada M, Kobayashi Y, Wakitani M, Uchida K, et al. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods 2005; 306:93-103; PMID:16236307; http://dx.doi.org/10.1016/j.jim.2005.07.025.

20. Griggs J, Zinkiewich-Peotti K. The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer 2009; 101:1807-12; PMID:19809433; http://dx.doi.org/10.1038/sj.bjc.6605349.

21. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27:3383-7; PMID:19584572; http://dx.doi.org/10.1200/JCO.2009.22.1507.

22. Shinkawa T, Nakamura K, Yamane N, Shoji-Hasoka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylgalactosamine of human IgG complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M216652000.

23. Schneuinger A, Grau R, Sondermann P, Schreitmueller T, Marti S, Zecher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol 2011; 48:1512-7; PMID:21570725; http://dx.doi.org/10.1016/j.molimm.2010.10.004.

24. Ferrara C, Stuart F, Sondermann P, Br¨unker P, Umata P. The carbohydrate at FcgammaRIII A26-16. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281:5032-6; PMID:16339541; http://dx.doi.org/10.1074/jbc.M510171200.

25. Nimmerjahn F, Ravetch JV. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10.1038/nri2060.
43. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelzi M, Tagliafuore E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10:5650-5; PMID:15355889; http://dx.doi.org/10.1158/1078-0432.CCR-04-0225.

44. Musolin A, Naldi N, Bottesi B, Pezzi M, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2 neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347065; http://dx.doi.org/10.1200/JCO.2007.14.8957.

45. Werner RG, Kopp K, Schluter M. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl 2007; 96:17-22; PMID:17391433; http://dx.doi.org/10.1111/j.1651-2227.2007.00199.x.

46. Ma S, Nashabeh W. Carbohydrate analysis of a chimeric monoclonal antibody by capillary electrophoresis with laser-induced fluorescence detection. Anal Chem 1999; 71:5185-92; PMID:10573965; http://dx.doi.org/10.1021/ac990376c.

47. Lu Y, Wong WL, Meng YG. A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection. J Immunol Methods 2006; 314:74-9; PMID:16814318; http://dx.doi.org/10.1016/j.jim.2006.05.011.

48. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200.

49. Iduogie EE, Presta LG, Gazzano-Santoro H, Topal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164:4178-84; PMID:10754313.